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Abstract
Importance—There is wide variation in the management of thyroid nodules identified on 
ultrasound imaging.
Objective—To quantify the risk of thyroid cancer associated with thyroid nodules based on their 
ultrasound characteristics.
Methods—Retrospective case-control study of patients who underwent thyroid ultrasound 
between January 1st, 2000 and March 30th, 2005. Thyroid cancers were identified through linkage 
with the California Cancer Registry.
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Results—8 806 patients underwent 11 618 thyroid ultrasound examinations during the study 
period including 105 subsequently diagnosed with thyroid cancer. Thyroid nodules were common 
in patients diagnosed with cancer (97%) and patients not diagnosed with thyroid cancer (56%). 
Three ultrasound nodule characteristics–micro-calcifications (odds ratio [OR] 8.1 [95% CI 3.8, 
17.3]), size greater than 2 cm (OR 3.6 [95% CI 1.7, 7.6]) and an entirely solid composition (OR 
4.0 [95% CI 1.7, 9.2] - were the only findings associated with the risk of thyroid cancer. If a single 
characteristic is used as an indication for biopsy, most patients with thyroid cancer would be 
detected (sensitivity .88 [95% CI .80, .94]) with a high false positive rate (.44 [95% CI .43, .45]) 
and a low likelihood ratio positive (2.0 [95% CI 1.8, 2.2]), and 56 biopsies will be performed per 
cancer diagnosed. If two characteristics were required for biopsy, the sensitivity and false positive 
rates would be lower (sensitivity 0.52 [95% CI 0.42, 0.62]; false positive rate 0.07 [95% CI 0.07, 
0.08]), the likelihood ratio positive would be higher (7.1 [95% CI 6.2, 8.2]), and only 16 biopsies 
will be performed per cancer diagnosed. In comparison to performing biopsy of all thyroid 
nodules greater than 5 mm, adoption of this more stringent rule requiring two abnormal nodule 
characteristics to prompt biopsy would reduce unnecessary biopsies by 90%, while maintaining a 
low risk of cancer, 5 per 1000 patients, for whom biopsy is deferred.
Conclusion—Thyroid ultrasound could be used to identify patients who have a low risk of 
cancer for whom biopsy could be deferred. Based on these results, these findings should be 
validated in a large prospective cohort.
INTRODUCTION
Ultrasound has replaced nuclear medicine as the most frequently used imaging test of the 
thyroid.1 The growth in the use of thyroid ultrasound by radiologists, endocrinologists and 
head and neck surgeons has led to the discovery of large numbers of asymptomatic thyroid 
nodules, which may occur in 50% or more of adults.2,3 as well as a rapid rise in the 
diagnosis of thyroid cancer. 4 In contrast, clinically apparent thyroid cancer is rare, affecting 
1/10,000 people annually, and fewer than 1% of individuals over the course of their lives.4–6 
Because of the high prevalence of nodules, and the rarity of symptomatic cancer, only a 
minority of thyroid nodules is malignant. Uncertainty about which nodules may harbor 
cancer and lack of evidence-based management guidelines has resulted in a myriad of 
conflicting recommendations regarding which nodules warrant biopsy, 6–17,18,19–21 frequent 
thyroid biopsies, and the over-diagnosis of thyroid cancers that would otherwise likely have 
remained asymptomatic in the absence of detection.4,22,23
While many studies have analyzed the association between the ultrasound characteristics of 
thyroid nodules and the risk of thyroid cancer, most studies are small and all limited their 
analysis to patients who underwent biopsy, where the decision to biopsy was influenced by 
the ultrasound result. 6–17,18,19–21 This ascertainment bias will overestimate the risk of 
cancer associated with thyroid biopsy and the accuracy of ultrasound.24–26 The information 
that is most important to patients and providers managing care includes quantifying the risk 
of cancer associated with a nodule with a particular imaging characteristic and no prior 
publication can accurately provide this information. This has hindered the development of 
an evidence-based strategy for determining which nodules should be biopsied because of an 
elevated cancer risk. The purpose of this study was to determine the ultrasound 
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characteristics that are associated with cancer, and to use this information for creating a 
standardized system for interpreting thyroid ultrasound.
METHODS
We conducted a retrospective, case-control study at the University of California San 
Francisco (UCSF), including consecutive patients who underwent thyroid ultrasound 
between January 1st, 2000 and March 30th 2005. A waiver of patient informed consent was 
obtained. Patients were excluded if they had a prior unilateral or bilateral thyroidectomy for 
benign or malignant disease.
Linkage to Population Cancer Registry
Cancers identified in the cohort were identified through linkage with the California Cancer 
Registry (CCR), a population-based cancer registry collecting cancer incidence and 
mortality data for all of California.27 The Registry is a collaboration between the Cancer 
Surveillance Section of California Department of Public Health, The Public Health Institute, 
and eight regional cancer registries, that by legislative mandate, have collected cancer 
incidence data from hospitals and other facilities across the state since 1988. The registry is 
certified by the North American Association of Central Cancer Registries (NAACCR) as 
meeting their highest standard for completeness of cancer ascertainment, reflecting capture 
of over 97% of cancers diagnosed in the state. 28 We included thyroid cancers diagnosed 
through March 30, 2007, allowing a minimum 2 years of follow-up after the last enrolled 
patient’s ultrasound, during which a cancer could be diagnosed, and at least 2 years further 
follow-up to ensure reporting to the registry.27 Patients diagnosed with non-thyroid 
malignant neoplasms (other than skin cancer) were excluded to prevent the inclusion of the 
rare, but theoretically possibly metastatic cancer to the thyroid, as these metastatic cancers 
would not be captured by the cancer registry. All patients diagnosed with cancer (cases, 
Table 1) and a sample of patients not diagnosed with cancer (controls), matched four to one 
to the cancer patients on age, sex and year of the ultrasound exam, were selected for detailed 
review of the sonogram.
Characterizations of the Ultrasound Examinations
We retrieved and reviewed the ultrasound examinations on 96 (91%) of the cancer patients 
on the Radiology PACS (Picture Archiving and Communication System) and 369 controls. 
Each ultrasound examination was reviewed independently by two board-certified 
radiologists blinded to cancer status. Disagreement was resolved by consensus. For each 
patient, each reviewer independently recorded the number, size and characteristics of all 
nodules >5 mm. There was good to outstanding agreement (kappas 0.73 to 1.0) in the 
categorization of the specific ultrasound characteristics.
Assignment of Cancer Status to Thyroid Nodules
In patients selected as controls, all nodules were considered benign. In 43 (44.8%) of cancer 
patients, a single nodule was identified and it was considered malignant. In 50 cancer 
patients (52.1%), multiple thyroid nodules were identified. To ensure correct attribution of 
cancer to the correct nodule, one of the authors was un-blinded, patient records (radiology, 
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pathology, surgery) were reviewed to determine which nodules were malignant. In the small 
number of cases that we were unable to determine which nodule harbored cancer, all 
nodules were considered malignant. Nodules in patients never diagnosed with thyroid cancer 
(n=428) and benign nodules in cancer patients (n=87) were combined to create our final 
control group of benign nodules (n=515). Note that 3 cancer patients (3.1%) did not have 
any nodules > 5 mm identified on their ultrasound imaging.
Analysis
We compared mean age, age group, sex and year of study between patients diagnosed with 
cancer and controls. We used Chi-square to determine whether the number of nodules varied 
by age group. We performed single predictor modeling to assess the association between 
specific ultrasound characteristics and cancer status using Generalized Estimating Equations 
(GEE), with a compound symmetry (exchangeable) correlation structure to account for the 
correlated outcomes between multiple nodules within a patient. For variables that were 
statistically significant in single predictor model, we calculated diagnostic accuracy statistics 
(sensitivity, specificity, likelihood ratios, predictive values).
To build the GEE models, we added variables that were statistically significant in single 
predictor models one at a time in the order of the effect size. Variables were retained if the 
associated p-value after inclusion was < 0.10 for that variable. The ultrasound characteristics 
that were retained in the final multiple-predictor model (micro-calcifications, size ≥ 2 cm 
and solid composition, Figure 1) were combined in various ways, via logical “and/or” 
criteria, to define an “abnormal ultrasound interpretation.” The ultrasound characteristics 
that were retained in the final multiple-predictor model (micro-calcifications, size ≥ 2 cm 
and solid composition, Figure 1) were combined in various ways, via logical “and/or” 
criteria, to define an “abnormal ultrasound interpretation.” The risk of cancer (predictive 
values) associated with each definition of an abnormal ultrasound was calculated, 
accounting for the sampling strategy in the entire cohort. The positive predictive value 
(PPV) is the risk of cancer for a patient that is found to have an abnormal ultrasound 
interpretation, and the negative predictive (NPV) is the probability of being cancer free if the 
ultrasound is negative. For each definition of an abnormal ultrasound, we calculated the 
number of cancers missed per 1000 ultrasounds performed. The number of patients needed 
to undergo a biopsy (NNTB) to detect a single cancer was defined as the inverse of the PPV. 
We performed several sensitivity analyses to determine whether implicit assumptions in the 
primary analysis were reasonable. More details on the analysis are provided in the online 
Appendix.
RESULTS
8 806 patients underwent 11 618 thyroid ultrasounds during the study period including 105 
diagnosed with thyroid cancer (incidence 0.9 cancers per 100 ultrasound examinations). The 
cancers were diagnosed 1 day to 6.1 years following ultrasound imaging, and among control 
patients, there was a mean follow up of 4.2 years (range 2.0 – 10.9). There were no 
significant differences in the matching variables between cases and controls.
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Thyroid nodules were common among patients diagnosed with thyroid cancer (96.9%) as 
well as patients not diagnosed with thyroid cancer (56.4%), Table 3. Among the 96 patients 
cases, 102 malignant nodules and 87 benign nodules were identified, with an increase in the 
number of nodules seen with advancing age. Among the 372 controls, 428 benign nodules 
were identified and the number of nodules did not vary with age.
Single Predictor Modeling Results
Several ultrasound findings were significantly associated with the odds of a nodule 
harboring cancer, Table 4. Micro-calcifications had the strongest association with cancer; 
38% of cancer nodules vs. 5% of benign nodules had micro-calcifications, reflecting 
approximately a 7 fold increase in the likelihood of cancer if micro-calcifications were seen 
(likelihood ratio positive 7.0 [95% CI 6.0, 8.2]) and a 30% reduction in the likelihood of 
cancer if micro-calcifications were not seen (likelihood ratio negative 0.65 [95% CI 0.56, 
0.76]). The corresponding odds ratio was 11.6 (95% CI 6.5, 20). Course calcifications, 
nodule composition, nodule echogenicity, central vascularity, margins and shape were also 
each significantly associated with cancer, but the magnitude of association was smaller, with 
odds ratios ranging from 1.6 to 2.8. Rim calcifications and comet tail artifacts, peripheral 
vascularity and the presence of a halo were not associated with the likelihood of cancer. The 
odds of cancer increased with nodule size, and the largest nodules had the greatest odds of 
cancer (likelihood ratio 1.8 [95% CI 1.5, 2.1], and OR 3.1, [95% CI 1.8, 5.2]) for nodules > 
2 cm compared with nodules under 1 cm. Simple cysts never reflected cancer.
Multiple Predictor Nodule Modeling Results
Only three nodule characteristics were significantly associated with the risk of cancer in the 
multiple predictor modeling; micro-calcifications (OR 8.1 [95% CI 3.8, 17.3]), size greater 
than 2 cm (OR 3.6 [95% CI 1.7, 7.6]), and an entirely solid composition (OR 4.0 [95% CI 
1.7, 9.2]), Table 5. The inclusion of the remaining nodule characteristics were not 
significantly associated with the risk of cancer, and including them in the definition of an 
abnormal nodule added less than 2% cancer detection.
The accuracy of the several definitions of an abnormal ultrasound are provided in Table 6. If 
any one of the three characteristics is used to prompt biopsy, most patients with thyroid 
cancer would be detected (sensitivity 0.88 [95% CI 0.80, 0.94]) at a false positive rate of 
0.44 (95% CI 0.43, 0.45). The high false positive rate of this approach is reflected in a low 
PPV (i.e., risk of cancer) of 1.8% (95% CI 1.5%, 2.2%) when a single characteristic is used 
to prompt biopsy, and 56 biopsies will be required per cancer diagnosed. If two abnormal 
ultrasound characteristics were required to prompt biopsy, the sensitivity and false positive 
rates would be lower (sensitivity 0.52 [95% CI 0.42, 0.62]; false positive rate 0.07 [95% CI 
0.07, 0.08]) and the risk of cancer in those with a suspicious ultrasound would be higher 
(PPV 6.2% [95% CI 4.7%, 8.7%]) and fewer biopsies, 16, would be required per cancer 
diagnosed. In comparison to existing guidelines that suggest biopsy of all thyroid nodules 
greater than 5 mm 7,8 adoption of this more stringent rule requiring two abnormal 
characteristics to prompt biopsy would reduce unnecessary biopsies by 90%, while 
maintaining a low risk of cancer in patients in whom biopsy is deferred (i.e., 5 cancers per 
1000 ultrasound examinations, 0.5%).
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The most specific definition of an abnormal ultrasound is one requiring all three abnormal 
characteristics to prompt biopsy, however this definition would detect only a small 
proportion of cancers (sensitivity 0.07 [95% CI 0.03, 0.14]), but would have a high 
likelihood ratio positive of 28 (95% CI 23, 34).
The tradeoff between the different definitions of an abnormal ultrasound and test accuracy is 
shown in Figure 2. As the number of criteria required to prompt biopsy increases, the 
number of missed cancers (false negatives) increases, and the number of patients who will 
be biopsied in order to detect a cancer will decrease. For example, if two criteria instead of 
one are required to prompt biopsy, the rate of missed cancers among patients who do not 
undergo biopsy increases from 2 to 5 per 1000 ultrasound examinations, while the number 
of biopsies needed to detect a cancer decreases from 56 to 16.
Predictive Values: Patient-Level Analysis
The risk of cancer based on the ultrasound appearance of the thyroid is shown in Table 7. 
The risk of cancer is low among patients with a homogeneous thyroid, where no nodules 
were identified (0.60 cancers per 1000). The risk of cancer is also low in patients where the 
only ultrasound characteristic is a simple cyst (0.32 cancers per 1000).
If the presence of a single abnormal characteristic is used to define an abnormal ultrasound, 
patients with a normal examination will have a risk of cancer of 2 per 1000, whereas patients 
with an abnormal exam will have a risk of cancer of 18 per 1000. If two or more 
characteristics are required to define an ultrasound exam as abnormal, patients with a 
negative exam will have a risk of cancer of 5 per 1000, and patients with an abnormal exam 
will have a risk of cancer of 62 per 1000, putting them in a moderate risk category. Micro-
calcifications are the most predictive characteristic and are associated with a cancer risk of 
82 per 1000. If an abnormal ultrasound is defined as one where micro-calcifications or a 
solid mass greater than 2 cm is seen, 58 cancers will be diagnosed per 1000 patients. When a 
solid mass > 2 cm with microcalcifications is seen, nearly all of these nodules harbor cancer. 
960 per 1000.
Alternative Analysis
The results were robust across all of the sensitivity analysis, and changed little when we 
varied our primary assumptions in the analysis.
DISCUSSION
Thyroid nodules are extremely common. Even among patients selected as controls in our 
study, 56% had thyroid nodules greater than 5 mm, and nearly a third had multiple nodules. 
In contrast to previous reports that have suggested the prevalence of cancer in thyroid 
nodules as high as 23%, we found only 1.6% of patients who had one or more thyroid 
nodules 5 mm or greater harbored cancer. Thus while thyroid nodules are common, the vast 
majority, 98.5%, are benign, highlighting the importance of being prudent in deciding which 
nodules should be sampled to reduce unnecessary biopsies.22 Unnecessary tissue sampling is 
not only invasive and costly, but leads to repeated sampling and unnecessary open surgical 
procedures, as up to one third of fine needle aspiration biopsies may be non-diagnostic, 
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requiring open surgical biopsy for diagnosis.8,9,29,30 We found that only three ultrasound 
characteristics: micro-calcifications, size ≥2 cm, and entirely solid composition – were 
statistically significantly associated with the risk of cancer, and that when used in 
combination, these three characteristics could be used to help determine which nodules 
should be sampled. Simple cysts are essentially never malignant and should not be 
sampled.31
There are many ways to characterize the accuracy of ultrasound. We believe the risk of 
cancer, PPV, is the most relevant to patients and physicians and ours is the first study that 
permits estimating this risk. A patient’s risk of harboring cancer ranges from 2 per 1000 
among patients whose thyroid ultrasound has none of the three characteristics identified; 18 
per 1000 if a patient has a nodule with a single characteristic; 62 per 1000 if a patient has a 
nodule with two abnormal characteristics; and 960 per 1000 if a patient has a nodule with all 
three characteristics. While there is growing concern regarding over-diagnosis and over 
treatment across all areas of medicine,22,32–34 there are no well-established guidelines of 
what risk is low enough that an imaging finding can be ignored. In other areas of diagnostic 
testing, for example when assessing patients at risk for acute coronary syndrome, or breast 
cancer (diseases with higher morbidity and mortality than thyroid cancer), often a risk of 
less than 1% or 0.5% is considered sufficiently low that further evaluation is deemed 
unnecessary. If a thyroid cancer risk < 0.5% is considered acceptable for those in whom 
biopsy is deferred, using micro-calcifications or the combined observations of a large (≥2 
cm) solid nodule as the only features to prompt biopsy reflects a good choice. In comparison 
with various guidelines that recommend biopsies in a larger number of patients13 limiting 
biopsy to nodules that fulfill this definition would reduce the number of biopsies by as much 
as 90%, while maintaining a low cancer rate of 5/1000 among individuals who do not 
undergo thyroid sampling. Most thyroid cancers have a favorable prognosis, with a 20-year 
survival greater than 97% seen even among patients who do not receive immediate 
treatment.10,23,34,35 Thus, given the favorable prognosis of most thyroid cancer even without 
treatment, a risk of cancer of 0.5% among those with a negative examination seems to 
balance between detection and unnecessary tissue sampling. Ongoing ultrasound 
surveillance of patients with nodules who do not meet the criteria for biopsy, is unlikely to 
prove beneficial given our results ascribe these patients a low risk of cancer for as long as 10 
years following imaging.
Our study was designed to determine how to reduce unnecessary and excessive thyroid 
surveillance and biopsy. Our study does not provide evidence as to whether the detection of 
thyroid cancers will lead to improved patient outcomes. There has been a recent rise in the 
observed incidence of small and micro thyroid cancer 4,5,35 without a corresponding change 
in thyroid cancer mortality rate, raising the question as to whether there is benefit to the 
earlier diagnosis or treatment of incidental thyroid cancer.22,23,36,37
A large number of previous studies have assessed the risk of cancer associated with the 
ultrasound appearance of the thyroid. 6,7,8,10,11–17,18,19–21,38–43 All previous studies will 
have inflated the association between nodule characteristics and cancer risk because they 
limited their analysis to nodules that underwent biopsy. For example, Ahn et al. compared 
various existing guidelines for prompting fine needle aspiration in a sample of 1398 patients 
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who had undergone biopsy. 13 In this sample, 20% of the included patients had cancer, 
contrasting with the 1.5% cancer rate in our study. He reports that the PPV value for cancer 
if a patient has micro-calcifications is 85.1%, whereas using our population-based approach 
without ascertainment bias, we found a PPV of 5.8%. We considered a large number of 
nodule characteristics endorsed by other authors 5, 7–26 but when put into the multiple 
predictor models, most of the characteristics were not significantly associated with cancer 
risk.
It is widely reported that the number of benign thyroid nodules increases with age. We 
observed this relationship among patients diagnosed with cancer, but not among patients 
without cancer.
The main strength of our study is the large sample size and the linkage of the cohort with 
data from a comprehensive cancer registry, which allows accurate assessment of the true 
underlying prevalence of cancer. The analysis has several limitations. We did not have 
accurate information about why patients underwent imaging – and the risk of cancer may 
vary by why patients were sent for sonograms. We did not stratify the results by the 
histological type of cancer, although the majority of included cancers were papillary cancer, 
as is the case for thyoid cancer in general. There are several ultrasound features that we did 
not assess, but these are rare, such as extra-capsular growth, or abnormal lymph nodes.11 We 
did not include the theoretical metastatic cancer to the thyroid as these would not be 
captured in the cancer registry data. However, we also linked to the local pathology 
database, and no cases of metastatic cancer were identified in the thyroid biopsies included.
The increased utilization 1 and improved technical quality of ultrasound has given rise to the 
detection of multiple morphologic characteristics, without clear criteria for what needs 
further evaluation, 22 resulting in greater tissue sampling and excessive treatment.23,35 In 
mammography, the adoption of uniform interpretation standards through BI-RADS (Breast 
Imaging Reporting and Data System) has been useful in allowing comparative effectiveness 
work in breast imaging, and efforts to standardize the interpretation of mammograms. 
Similar adoption of uniform standards for interpreting of thyroid sonograms, would be a first 
step toward standardizing the diagnosis and treatment of thyroid cancer, and limiting 
unnecessary diagnostic testing and treatment.
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Images of thyroid nodules that are entirely solid (Figures 1A–1D), and that demonstrate 
micro-calcifications (Figures 1A–1C)
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